DAIICHI SANKYO CO., LTD. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.14 EUR | +2.53% |
|
+9.79% | +24.64% |
| Sales 2024 | 1,602B 10.22B 9.54B 814B | Sales 2025 * | 1,761B 11.24B 10.49B 895B | Capitalization | 9,607B 61.31B 57.21B 4,884B |
|---|---|---|---|---|---|
| Net income 2024 | 201B 1.28B 1.2B 102B | Net income 2025 * | 186B 1.18B 1.1B 94.33B | EV / Sales 2024 | 5.72 x |
| Net cash position 2024 * | 556B 3.55B 3.31B 283B | Net cash position 2025 * | 455B 2.9B 2.71B 231B | EV / Sales 2025 * | 5.2 x |
| P/E ratio 2024 |
45.6
x | P/E ratio 2025 * |
49
x | Employees | 17,435 |
| Yield 2024 |
1.05% | Yield 2025 * |
1.14% | Free-Float | 97.04% |
More Fundamentals
* Assessed data
More news
Latest transcript on Daiichi Sankyo Co., Ltd.
More recommendations
More press releases
More news
| 1 day | +2.53% | ||
| 1 week | +9.79% | ||
| Current month | +2.05% | ||
| 1 month | +5.30% | ||
| 3 months | +13.73% | ||
| 6 months | +22.28% | ||
| Current year | +24.64% |
1 week
27.80
30.40
1 month
26.6130.40
Current year
24.4633.13
1 year
22.3534.48
3 years
15.0534.80
5 years
14.2334.80
10 years
3.7234.80
| Managers | Title | Age | Since |
|---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 31/03/07 |
Hiroyuki Okuzawa
PSD | President | 61 | 31/03/17 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 31/05/19 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 31/05/19 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 31/03/07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 30.4 | +3.44% | 180 |
| 26/04/24 | 29.39 | +0.41% | 0 |
| 25/04/24 | 29.27 | +3.06% | 135 |
| 24/04/24 | 28.4 | +2.16% | 150 |
| 23/04/24 | 27.8 | +0.40% | 65 |
Delayed Quote Deutsche Boerse AG, April 29, 2024 at 03:38 pm
More quotes
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
30/07/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
5,010
JPY
Average target price
5,673
JPY
Spread / Average Target
+13.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.92% | 661B | |
| +26.74% | 566B | |
| -6.52% | 352B | |
| +20.39% | 332B | |
| +3.13% | 283B | |
| +13.45% | 231B | |
| +4.70% | 200B | |
| -9.41% | 195B | |
| -5.11% | 145B |
- Stock Market
- Equities
- 4568 Stock
- D4S Stock
